Conclusion
(i) Physicians are faced with several therapeutic challenges when ET coexists with solid tumours.
(ii) )ese should be managed on an individual basis.
(iii) One should take into consideration the risk of thrombosis and the therapeutic approach for solid tumours in the management of these patients.
(iv) Extended VTE prophylaxis during chemotherapy may be needed in select cases.
(v) ET and breast cancer both have favourable outcomes, and therefore, treatment for one should not preclude treatment for the other.
